MicroRNA expression levels in early and long-term period following heart transplantation

Objective: to conduct comparative analysis of the expression levels of microRNA-101, microRNA-142, microRNA- 27, microRNA-339 and microRNA-424 in patients with severe chronic heart failure and in heart recipients in the early and long-term period following heart transplantation and to determine the association with acute transplant rejection. Materials and methods. The study included 46 heart recipients, among whom were 36 men (78.3%); the average age of the recipients was 47.7 ± 10.8 (16 to 67) years, and 12 patients with end-stage chronic heart failure, among whom were 8 men (66.7%); the average age of the patients was 46.1 ± 6.4 (37 to 64) years. The control group consisted of 12 healthy individuals, not significantly different by gender and age. microRNA expression levels in blood plasma were determined through quantitative polymerase chain reaction (Q-PCR). Transplant rejection was verified via morphological analysis of endomyocardial biopsy specimens. Results. Blood plasma of patients with end-stage chronic heart failure had significantly higher expression rates of microRNA-101, microRNA-27, microRNA-339 and microRNA-424 than in healthy individuals (p < 0.02). In the early stages following transplantation, the expression levels of microRNA-101 and microRNA-27 in heart recipients were significantly lower than in patients with severe chronic heart failure (p < 0.003). A year or more after transplantation, there were no significant differences in the expression levels of microRNA-101, microRNA- 142, and microRNA-339 in heart recipients and in healthy individuals. In recipients with acute rejection, the expression levels of microRNA-101 and microRNA-27 significantly differed from that of recipients without signs of rejection (p = 0.04 and p = 0.03, respectively). Conclusion. The obtained data on changes in the expression levels of microRNA-101 and microRNA-27 in heart recipients with acute transplant rejection suggests possible diagnostic value of these biomarkers in determining the risk of rejection.

heart transplantation, microRNA, chronic heart failure, biomarkers, rejection

1. Kransdorf EP, Kobashigawa JA. Novel molecular approaches to the detection of heart transplant rejection. Per Med. 2017 Jul; 14 (4): 293–297.

2. Crespo-Leiro MG, Barge-Caballero G, Couto-Mallon D. Noninvasive monitoring of acute and chronic rejection in heart transplantation. Curr Opin Cardiol. 2017 Mar 16. doi: 10.1097/HCO.0000000000000400. [Epub ahead of print].

3. van Gelder T. Biomarkers in solid organ transplantation. Br J Clin Pharmacol. 2017 Dec; 83 (12): 2602–2604.

4. Velikiy DA, Gichkun OE, Shevchenko AO. MikroRNK: rol’ v razvitii serdechno-sosudistykh zabolevanij, perspektivy’ klinicheskogo primeneniya. Klinicheskaya laboratornaya diagnostika. 2018; 63 (7): 403–409. [In Russ, English abstract].

5. Savic-Radojevic A, Pljesa-Ercegovac M, Matic M et al. Novel biomarkers of heart failure. Advances In Clinical Chemistry. 2017; 79: 93–152.

6. Starling RC, Stehlik J, Baran DA et al. Multicenter analysis of immune biomarkers and heart transplant outcomes: results of the clinical trials in organ transplantation- 05 study. American Journal of Transplantation. 2016; 16: 121–136.

7. Di Francesco A, Fedrigo M, Santovito D, Natarelli L, Castellani C, De Pascale F et al. MicroRNA signatures in cardiac biopsies and detection of allograft rejection. J Heart Lung Transplant. 2018 Nov; 37 (11): 1329–1340.

8. Shah P, Bristow MR, Port JD. MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential. Curr Heart Fail Rep. 2017 Dec; 14 (6): 454–464.

9. Khush K, Zarafshar S. Molecular Diagnostic Testing in Cardiac Transplantation. Curr Cardiol Rep. 2017 Oct 13; 19 (11): 118.

10. Gautier SV, Shevchenko AO, Popcov VN. Pacient s transplantirovannym serdcem: rukovodstvo dlya vrachej po vedeniyu pacientov, perenesshih transplantaciyu serdca. M.: Triada, 2014: 144.

11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta C(T)) Method. Methods. 2001 Dec; 25 (4): 402–408.

12. Zhang XL, An BF, Zhang GC. MiR-27 alleviates myocardial cell damage induced by hypoxia/reoxygenation via targeting TGFBR1 and inhibiting NF-κB pathway. Kaohsiung J Med Sci. 2019 Oct; 35 (10): 607–614.

13. Li X, Zhang S, Wa M, Liu Z, Hu S. MicroRNA-101 Protects Against Cardiac Remodeling Following Myocardial Infarction via Downregulation of Runt-Related Transcription Factor 1. J Am Heart Assoc. 2019 Dec 3; 8 (23): e013112.

14. Sukma Dewi I, Hollander Z, Lam KK, McManus JW, Tebbutt SJ, Ng RT et al. Association of Serum MiR-142- 3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation. PLoS One. 2017; 12 (1): e0170842.